Navigation Links
Hard-to-Treat Leukemia Cell Subtype Identified
Date:1/14/2009

Discovery suggests new treatments for aggressive form of childhood disease, study says

WEDNESDAY, Jan. 14 (HealthDay News) -- Researchers say they may have identified a subtype of T-lymphoblastic leukemia (T-ALL) in children that does not respond to standard intensive chemotherapy.

Approximately 20 percent of children with T-ALL fair poorly on the same chemotherapy treatments that cure others with the disease, and doctors had been unable to explain why and which patients were least likely to improve.

Reporting online Jan. 14 and in the February edition of The Lancet Oncology, a team at St. Jude Children's Research Hospital in Memphis, Tenn., found that those who didn't respond to treatment had early T-cell precursors (ETPs). Believed to be recent migrants from the bone marrow to the thymus, they are substantially different to the lymphoid cells that standard chemotherapy normally attacks and may be resistant to it, the researchers said.

In a U.S.-based group of study participants, nearly three-quarters of those with ETP-ALL suffered a relapse within a decade, compared with only 10 percent of typical T-ALL patients. In an Italian group of participants, 57 percent of ETP-ALL patients had a relapse within two years, compared with only 14 percent of typical T-ALL patients.

"The high risk of remission failure or subsequent relapse for patients with ETP-ALL, if treated with standard intensive chemotherapy, indicates the need for alternative approaches to treatment," Dr. Dario Campana of St. Jude's department of oncology, said in a news release issued by the journal.

Campana and his team suggested trying alternate treatments for ETP-ALL, such as myeloablative therapy (high-dose chemotherapy) followed by haemopoietic stem-cell transplantation in first remission while other therapies are investigated.

More information

The U.S. National Cancer Institute has more about childhood leukemia.



-- Kevin McKeever



SOURCE: The Lancet Oncology, news release, Jan. 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Revolutionary New Technique Uses Onyx to Fill Hard-To-Treat Aneurysms
2. Relaxation training may improve control of hard-to-treat systolic hypertension
3. Blood-clotting protein modified for people with hard-to-treat hemophilia
4. Tackling Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes
5. Tackling a hard-to-treat childhood cancer by targeting epigenetic changes
6. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
7. Study finds heart failure is rare among leukemia patients on imatinib
8. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
9. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. Novel strategy under study for aggressive leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hard-to-Treat Leukemia Cell Subtype Identified
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: